Lori D Dwyer-Nield

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. ncbi Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains
    Lori D Dwyer-Nield
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA
    Int J Cancer 126:125-32. 2010
  2. ncbi Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis
    Lori R Kisley
    Department of Pharmaceutical Sciences, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver 80262, USA
    Cancer Res 62:6850-6. 2002
  3. ncbi Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies
    Kumaraguruparan Ramasamy
    Department of Pharmaceutical Sciences, University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado, USA
    Clin Cancer Res 17:753-61. 2011
  4. ncbi Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia
    Katherine A Peebles
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado 80215, USA
    Mol Carcinog 46:887-900. 2007
  5. ncbi Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines
    Lori D Dwyer-Nield
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Carcinogenesis 26:1196-206. 2005
  6. ncbi Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization
    Elizabeth F Redente
    Department of Pharmaceutical Sciences, University of Colorado Denver, 12700 East 19th Avenue, Aurora, CO 80045, USA
    Am J Pathol 176:2972-85. 2010
  7. ncbi Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing
    Laura K Zerbe
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado 802262, USA
    Mol Carcinog 41:187-96. 2004
  8. ncbi Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis
    Laura K Zerbe
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Box C238, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Cancer Lett 241:197-202. 2006
  9. ncbi Silibinin modulates TNF-α and IFN-γ mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells
    Alpna Tyagi
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Aurora, Colorado 80045, USA
    Mol Carcinog 51:832-42. 2012
  10. ncbi Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice
    Laura K Zerbe
    Department of Pharmaceutical Sciences, University of Colorado at Denver and Health Sciences Center, 4200 East Ninth Avenue, Box C238, Denver, CO, 80262, USA
    Cancer Chemother Pharmacol 62:605-20. 2008

Collaborators

Detail Information

Publications21

  1. ncbi Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains
    Lori D Dwyer-Nield
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA
    Int J Cancer 126:125-32. 2010
    ..DNA repair genes not located on Chr 6 may determine the nature of Kras mutations. CSS-6 mice are a valuable resource for testing the ability of candidate genes to modulate lung carcinogenesis...
  2. ncbi Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis
    Lori R Kisley
    Department of Pharmaceutical Sciences, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver 80262, USA
    Cancer Res 62:6850-6. 2002
    ..The substantial (80%) reduction in lung tumor multiplicity in iNOS (-/-) mice strongly supports examining iNOS-specific inhibitors as potential lung cancer chemopreventive agents...
  3. ncbi Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies
    Kumaraguruparan Ramasamy
    Department of Pharmaceutical Sciences, University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado, USA
    Clin Cancer Res 17:753-61. 2011
    ..Herein, we genetically confirmed this role of iNOS and evaluated the chemopreventive efficacy of silibinin in carcinogen-treated B6/129 wild-type (WT) and iNOS(-/-) mice...
  4. ncbi Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia
    Katherine A Peebles
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado 80215, USA
    Mol Carcinog 46:887-900. 2007
    ....
  5. ncbi Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines
    Lori D Dwyer-Nield
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Carcinogenesis 26:1196-206. 2005
    ....
  6. ncbi Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization
    Elizabeth F Redente
    Department of Pharmaceutical Sciences, University of Colorado Denver, 12700 East 19th Avenue, Aurora, CO 80045, USA
    Am J Pathol 176:2972-85. 2010
    ..Manipulating TAM function or depleting TAMs may provide novel therapeutic strategies for preventing and treating many types of cancer...
  7. ncbi Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing
    Laura K Zerbe
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado 802262, USA
    Mol Carcinog 41:187-96. 2004
    ..These changes are influenced by tumor histology and may be associated with production of variant CD44 mRNA isoforms...
  8. ncbi Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis
    Laura K Zerbe
    Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Box C238, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Cancer Lett 241:197-202. 2006
    ..The formation of microscopic lesions is thus genetically dependent, but whether they continue to grow or regress depends on how they were induced...
  9. ncbi Silibinin modulates TNF-α and IFN-γ mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells
    Alpna Tyagi
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Aurora, Colorado 80045, USA
    Mol Carcinog 51:832-42. 2012
    ....
  10. ncbi Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice
    Laura K Zerbe
    Department of Pharmaceutical Sciences, University of Colorado at Denver and Health Sciences Center, 4200 East Ninth Avenue, Box C238, Denver, CO, 80262, USA
    Cancer Chemother Pharmacol 62:605-20. 2008
    ..We evaluated whether erlotinib is also effective at an early stage of primary lung tumorigenesis in a carcinogen-induced lung tumor model in mice...
  11. ncbi The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers
    Jason M Fritz
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado 80045, USA
    J Thorac Oncol 5:254-7. 2010
    ..In a mouse model of human cancer, A/J and BALB/cBy mice treated with the tobacco carcinogen, 3-methylcholanthrene (MCA), followed by butylated hydroxytoluene (BHT)-elicited chronic inflammation develop a high multiplicity of lung tumors...
  12. ncbi Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3
    Alpna Tyagi
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Denver, CO 80262, USA
    Cancer Prev Res (Phila) 2:74-83. 2009
    ....
  13. ncbi Responses of tumorigenic and non-tumorigenic mouse lung epithelial cell lines to electrophilic metabolites of the tumor promoter butylated hydroxytoluene
    Yude Sun
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East 9th Avenue Box C238, Denver, CO 80262, USA
    Chem Biol Interact 145:41-51. 2003
    ..Normal cells are destroyed more readily which allows neoplastic cells to expand their proliferation...
  14. ncbi Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation
    Jason M Fritz
    Department of Pharmaceutical Sciences, Skagg School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E, Montview Blvd, C 238 V20 4460, Aurora, CO 80045, USA
    Mol Cancer 10:76. 2011
    ....
  15. ncbi Effect of silibinin on the growth and progression of primary lung tumors in mice
    Rana P Singh
    4200 E. 9th Ave, Box C238, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Cancer Center, Denver, CO 80262, USA
    J Natl Cancer Inst 98:846-55. 2006
    ..CONCLUSIONS: Silibinin inhibits lung tumor angiogenesis in an animal model and merits investigation as a chemopreventive agent for suppressing lung cancer progression...
  16. ncbi Lung tumor growth is stimulated in IFN-gamma-/- mice and inhibited in IL-4Ralpha-/- mice
    Elizabeth F Redente
    Department of Pharmaceutical Sciences, University of Colorado at Denver, Aurora, CO 80045, USA
    Anticancer Res 29:5095-101. 2009
    ..Herein the biological consequences of forcing classical (M1) or alternative (M2) macrophage activation on lung tumor development are examined...
  17. ncbi Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation
    Elizabeth F Redente
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA
    J Leukoc Biol 88:159-68. 2010
    ..tuberculosis infection...
  18. ncbi Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice
    Lori R Kisley
    Department of Pharmaceutical Sciences, University of Colorado Cancer Center, Denver CO 80262, USA
    Carcinogenesis 23:1653-60. 2002
    ..As the production of eicosanoids in addition to PGE2 is also inhibited by celecoxib, and as celecoxib has COX-independent interactions, its effects on tumor formation may vary in different organ systems...
  19. ncbi Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy
    Yingnian Lu
    GlobeImmune Inc, 12635 E. Montview Boulevard, Aurora, CO 80010, USA
    Cancer Res 64:5084-8. 2004
    ..In combination with the genomic sequencing of tumors in patients, the yeast-based immunotherapeutic approach could be applied to treat Ras mutation-bearing human cancers...
  20. ncbi Morphological assessment of apoptosis in human lung cells
    Lori D Dwyer-Nield
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO, USA
    Methods Mol Med 74:283-97. 2003
  21. ncbi Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6-di-tert-butyl-4-methylphenol (BHT) and 2-tert-butyl-4-methyl-6-iso-propylphenol: correlation with quinone methide reactivity
    Rene Kupfer
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chem Res Toxicol 15:1106-12. 2002
    ....